Shots:
- Insilico has initiated a P-III trial assessing Rentosertib vs PBO in ~320 pts with idiopathic pulmonary fibrosis (IPF) over 52wks.
- Earlier P-IIa (GENESIS-IPF) trial data showed Rentosertib (30mg, QD or BID, & 60mg, QD) met its 1EP, plus 60mg arm demonstrated a mean FVC change of +98.4mL vs -20.3mL at 12wks.
- Rentosertib, an oral small-molecule inhibitor targeting TNIK, was discovered using Insilico’s Pharma.AI platform, with PandaOmics identifying the novel TNIK target and Chemistry42 designing the small molecule
Ref: PRnewswire | Image: Insilico Medicine | Press Release
Related News: Insilico Medicine Collaborates with Takeda to Advance AI Drug Discovery
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
